Disease Landscape and Forecast Insights

MARKET OUTLOOK Pancreatic cancer is a life-threatening disease with a survival rate of less than 10% and with no improvements in the last 40 years. Owing to the lack of rapid diagnostics, the…

MARKET OUTLOOK The European atopic dermatitis (AD) market has entered a new era. In 2017, IL-4/13 inhibitor Dupixent (Sanofi/Regeneron) became the first targeted biologic to be approved for…

With the launch of four adalimumab biosimilars into the European market in October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), and Hyrimoz (Sandoz)—competition within the already…

Market Outlook Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, presents as hives that persist daily or almost daily for six weeks or longer without an obvious…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

MARKET OUTLOOK The current treatment algorithm for NSCLC is dominated by targeted branded therapies, reflecting its biomarker-driven treatment landscape. The EGFR and ALK TKIs Tagrisso and…

The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies into new patient populations. Examples include…

The treatment of neuropathic pain involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid…

Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in…

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with…

Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) market. Most inpatients are successfully treated empirically with such agents, making it difficult for…